Parallax Volatility Advisers’s Carisma Therapeutics CARM Stock Holding History

Parallax Volatility Advisers’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,617	Closed	-$44.1K	–	2753
2022 Q4	$44.1K	Hold	3,617	–	–	﹤0.01%	2386
2022 Q3	$31K	Hold	3,617	–	–	﹤0.01%	2675
2022 Q2	$59K	Hold	3,617	–	–	﹤0.01%	2441
2022 Q1	$44K	Hold	3,617	–	–	﹤0.01%	2495
2021 Q4	$59K	Sell	3,617 -20	-0.5%	-$403	﹤0.01%	1816
2021 Q3	$58K	Buy	+3,637	New	+$175K	﹤0.01%	1825
2019 Q1	–	Sell	-2	Closed	–	–	2832
2018 Q4	$0	Buy	+2	New	+$64	﹤0.01%	2959
2018 Q3	–	Sell	-907	Closed	-$35.3K	–	2616
2018 Q2	$35K	Sell	907 -931	-51%	-$41K	﹤0.01%	1668
2018 Q1	$39K	Hold	1,838	–	–	﹤0.01%	1618
2017 Q4	$30K	Buy	+1,838	New	+$34.2K	﹤0.01%	3486

Other funds holding CARM

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallax Volatility Advisers's CARM Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 3,617 shares — an estimated $44.1K sold.

Parallax Volatility Advisers first reported a position in CARM in Q4 2017 and held it in 10 quarters. The position peaked at $59K in Q2 2022. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

Parallax Volatility Advisers reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 3,617 Carisma Therapeutics shares in Q1 2023, an estimated $44.1K.
Parallax Volatility Advisers first reported a position in Carisma Therapeutics in Q4 2017 and held it in 10 quarters.
Parallax Volatility Advisers's Carisma Therapeutics position peaked at $59K in Q2 2022.
37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.